LUNG — Pulmonx Income Statement
0.000.00%
Last trade - 00:00
- $291.48m
- $211.62m
- $68.68m
- 38
- 21
- 38
- 23
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 32.6 | 32.7 | 48.4 | 53.7 | 68.7 |
Cost of Revenue | |||||
Gross Profit | 22.4 | 21.2 | 35.6 | 39.9 | 50.8 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 50.4 | 65.1 | 95.7 | 112 | 131 |
Operating Profit | -17.8 | -32.3 | -47.3 | -58.6 | -61.9 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -20.3 | -32 | -48.3 | -58.6 | -60.3 |
Provision for Income Taxes | |||||
Net Income After Taxes | -20.7 | -32.2 | -48.7 | -58.9 | -60.8 |
Net Income Before Extraordinary Items | |||||
Net Income | -20.7 | -32.2 | -48.7 | -58.9 | -60.8 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -20.7 | -32.2 | -48.7 | -58.9 | -60.8 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.61 | -0.903 | -1.35 | -1.59 | -1.6 |
Dividends per Share |